Retinoids for prevention and treatment of actinic keratosis

Mayra Ianhez, Luiz Fernando Fróes Fleury Jr, Hélio Amante Miot, Edileia Bagatin, Mayra Ianhez, Luiz Fernando Fróes Fleury Jr, Hélio Amante Miot, Edileia Bagatin

Abstract

Actinic keratosis is a common cause of dermatological consultations and it presents a strong association with squamous cell carcinoma. Many substances are used for treatment and prevention, such as retinoids. Nevertheless, many studies on retinoids emphasize their application in treating and preventing non melanoma skin cancers. In this article, we reviewed studies about systemic and topical retinoids used with immunocompetent patients and organ transplant recipients with actinic keratosis, as primary or secondary outcomes. The majority of these papers pointed to a reduction in actinic keratosis count after treatment with retinoids. However, studies need to be better-defined in order to address the lack of a standardized dose, the absence of control groups, the low number of patients and short follow-up periods. Blind, randomized and controlled clinical trials with adequate sample sizes, specifically focused on actinic keratosis, are needed to clarify the real benefit of topical and/or oral retinoids. Comparison of efficacy and safety between oral and topical retinoids in the prevention and treatment of non-melanoma skin cancers and actinic keratosis is an essential pre requisite to establish new strategies to control these conditions.

Conflict of interest statement

Conflict of interest: None

References

    1. Salasche SJ. Epidemiology of actinic keratosis and squamous cell carcinoma. J Am Acad Dermatol. 2000;42:4–7.
    1. Sociedade Brasileira de Dermatologia Nosologic profile of dermatologic visits in Brazil. An Bras Dermatol. 2006;81:549–558.
    1. Campione E, Diluvio L, Paternò EJ, Chimenti S. Topical treatment of actinic keratosis with piroxicam 1% gel: a preliminary open-label study utilizing a new clinical score. Am J Clin Dermatol. 2010;11:45–50.
    1. Tutrone WD, Saini R, Caglar S, Weinberg JM, Crespo J. Topical therapy for actinic keratosis, I: 5-Fluorouracil and imiquimod. Cutis. 2003;71:365–370.
    1. Zhao B, He YY. Recent advances in the prevention and treatment of skin cancer using photodynamic therapy. Expert Rev Anticancer Ther. 2010;10:1797–1809.
    1. Campbell RM, DiGiovanna JJ. Skin cancer chemoprevention with systemic retinoids: an adjunct in the management of selected high-risk patients. Dermatol Ther. 2006;19:306–314.
    1. Lotan R. Effects of vitamin A and its analogs (retinoids) on normal and neoplastic cells. Biochim Biophys Acta. 1980;605:33–91.
    1. Von Stuttgen G. Zur lokalbehandllung von keratosen mit vitamin-A saute. Dermatologica. 1962;124:65–80.
    1. Marquez C, Bair SM, Smithberger E, Cherpelis BS, Glass LF. Systemic retinoids for chemoprevention of non-melanoma skin cancer in high-risk patients. J Drugs Dermatol. 2010;9:753–758.
    1. Peck GL, Gross EG, Butkus D, DiGiovanna JJ. Chemoprevention of basal cell carcinoma with isotretinoin. J Am Acad Dermatol. 1982;6:815–823.
    1. Kraemer KH, DiGiovanna JJ, Moshell AN, Tarone RE, Peck GL. Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N Engl J Med. 1988;318:1633–1637.
    1. Bagatin E, Parada MO, Miot HA, Hassun KM, Michalany N, Talarico S. A randomized and controlled trial about the use of oral isotretinoin for photoaging. Int J Dermatol. 2010;49:207–214.
    1. Lens M, Medenica L. Systemic retinoids in chemoprevention of non-melanoma skin cancer. Expert Opin Pharmacother. 2008;9:1363–1374.
    1. Wright TI, Spencer JM, Flowers FP. Chemoprevention of non-melanoma skin cancer. J Am Acad Dermatol. 2006;54:933–946.
    1. Mrass P, Rendl M, Mildner M, Gruber F, Lengauer Cancer Res. 2004;64:6542–6548.
    1. Cheepala SB, Yin W, Syed Z, Gill JN, McMillian A, Kleiner HE, et al. Identification of the B-Raf/Mek/Erk MAP kinase pathway as a target for all-trans retinoic acid during skin cancer promotion. Mol Cancer. 2009;8:27–27.
    1. Sorg O, Tran C, Saurat JH. Cutaneous vitamins A and E in the context of ultraviolet- or chemically-induced oxidative stress. Skin Pharmacol Appl Skin Physiol. 2001;14:363–372.
    1. Moriarty M, Dunn J, Darragh A, Lambe R, Brick I. Etretinate in treatment of actinic keratosis. A double-blind crossover study. Lancet. 1982;1:364–365.
    1. DiGiovanna JJ. Retinoid chemoprevention in the high-risk patient. J Am Acad Dermatol. 1998;39:S82–S85.
    1. De Graaf YGL, Euvrard NS, Bavinck JNB. Systemic and topical retinoids in the management of skin cancer in organ transplant recipients. Dermatol Surg. 2004;30:656–661.
    1. Torras H. Retinoids in aging. Dermatol Clin. 1996;14:207–215.
    1. Kligman AM, Fulton JE Jr, Plewig G. Topical vitamin A acid in acne vulgaris. Arch Dermatol. 1969;99:469–476.
    1. Cordero A. La vitamina A acida en la piel senil. Actua Ter Dermatol. 1983;6:49–49.
    1. Kligman AM, Grove GL, Hirose R, Leyden JJ. Topical tretinoin for photoaged skin. J Am Acad Dermatol. 1986;15:836–859.
    1. Rook AH, Jaworsky C, Nguyen T, Grossman RA, Wolfe JT, Witmer WK, et al. Beneficial effect of low-dose systemic retinoid in combination with topical tretinoin for the treatment and prophylaxis of premalignant and malignant skin lesions in renal transplant recipients. Transplantation. 1995;59:714–719.
    1. Kelly JW, Sabto J, Gurr FW, Bruce F. Retinoids to prevent skin cancer in organ transplant recipients. Lancet. 1991;338:1407–1407.
    1. Bavinck JN, Tieben LM, Van der Woude FJ, Tegzess AM, Hermans J, ter Schegget J, et al. Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study. J Clin Oncol. 1995;13:1933–1938.
    1. De Sévaux RG, Smit JV, de Jong EM, van de Kerkhof PC, Hoitsma AJ. Acitretin treatment of premalignant and malignant skin disorders in renal transplant recipients: clinical effects of a randomized trial comparing two doses of acitretin. J Am Acad Dermatol. 2003;49:407–412.
    1. Bollag W, Ott F. Retinoic acid: topical treatment of senile or actinic keratosis and basal cell carcinomas. Agents Actions. 1970;1:172–175.
    1. Hughes BR, Marks R, Pearse AD, Gaskell SA. Clinical response and tissue effects of etretinate treatment of patients with solar keratosis and basal cell carcinoma. J Am Acad Dermatol. 1988;18:522–529.
    1. Euvrard S, Verschoore M, Touraine JL, Dureau G, Cochat P, Czernielewski J, et al. Topical retinoids for warts and keratosis in transplant recipients. Lancet. 1992;340:48–49.
    1. Majewski S, Skopinska M, Bollag W, Jablonska S. Combination of isotretinoin and calcitriol for precancerous and cancerous skin lesions. Lancet. 1994;344:1510–1511.
    1. Yuan ZF, Davis A, Macdonald K, Bailey RR. Use of acitretin for the skin complications in renal transplant recipients. N Z Med J. 1995;108:255–256.
    1. Euvrard S, Kanitakis J, Claudy A. Topical retinoids for the management of dysplastic epithelial lesions. In: Euvrard S, Kanitakis J, Claudy A, editors. Skin Diseases after Organ Transplantation. Montrouge: John Libbey Eurotext; 1998. pp. 175–182.
    1. George R, Weightman W, Russ GR, Bannister KM, Matthew TH. Acitretin for chemoprevention of non-melanoma skin cancers in renal transplant recipients. Australas J Dermatol. 2002;43:269–273.
    1. McNamara IR, Muir J, Galbraith AJ. Acitretin for prophylaxis of cutaneous malignancies after cardiac transplantation. J Heart Lung Transplant. 2002;21:1201–1205.
    1. Shuttleworth D, Marks R, Griffin PJ, Salaman JR. Treatment of cutaneous neoplasia with etretinate in renal transplant recipients. Q J Med. 1988;68:717–725.
    1. McKenna DB, Murphy GM. Skin cancer chemoprophylaxis in renal transplant recipients: 5 years of experience using low-dose acitretin. Br J Dermatol. 1999;140:656–660.
    1. Kligman AL, Thorne EG. Topical therapy of actinic keratosis with tretinoin. In: Marks R, editor. Retinoids in Cutaneous Malignancy. Oxford: Blackwell Scientific Publications; 1991. pp. 66–73.
    1. Misiewicz J, Sendagorta E, Golebiowska A, Lorenc B, Czarnetzki BM, Jablonska S. Topical treatment of multiple actinic keratosis of the face with arotinoid methyl sulfone (Ro 14-9706) cream versus tretinoin cream: a double-blind, comparative study. J Am Acad Dermatol. 1991;24:448–451.
    1. Alirezai M, Dupuy P, Amblard P, Kalis B, Souteyrand P, Frappaz A, et al. Clinical evaluation of topical isotretinoin in the treatment of actinic keratosis. J Am Acad Dermatol. 1994;30:447–451.
    1. Moglia D, Formelli F, Baliva G, Bono A, Accetturi M, Nava M, et al. Effects of topical treatment with fenretinide (4-HPR) and plasma vitamin A levels in patients with actinic keratosis. Cancer Lett. 1996;110:87–91.
    1. Campanelli A, Naldi L. A retrospective study of the effect of long-term topical application of retinaldehyde (0.05%) on the development of actinic keratosis. Dermatology. 2002;205:146–152.
    1. Smit JV, Cox S, Blokx WA, van de Kerhof PC, de Jongh GJ, de Jong EM. Actinic keratosis in renal transplant recipients does not improve with calcipotriol cream and all-trans retinoic acid cream as monotherapies or in combination during a 6week treatment period. Br J Dermatol. 2002;147:816–818.
    1. Smit JV, de Sévaux RG, Blokx WA, van de Kerkhof PC, Hoitsma AJ, de Jong EM. Acitretin treatment in (pre)malignant skin disorders of renal transplant recipients: Histologic and immunohistochemical effects. J Am Acad Dermatol. 2004;50:189–196.
    1. Purcell SM, Pierre DK, Dixon SL, Spielvogel RL. Chemoprevention of actinic keratosis with topical all-trans-retinoic acid. J Invest Dermatol. 1986;86:501.
    1. Thompson SC, Jolley D, Marks R. Reduction of solar keratosis by regular sunscreen use. N Engl J Med. 1993;329:1147–1151.
    1. Ulrich C, Jürgensen JS, Degen A, Hackethal M, Ulrich M, Patel MJ, et al. Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study. Br J Dermatol. 2009;161:S78–S84.
    1. Di Giovanna JJ. Systemic retinoid therapy. Dermatol Clin. 2001;19:161–167.
    1. De Marchi MA, Maranhão RC, Brandizzi LI, Souza DR. Effects of isotretinoin on the metabolism of triglyceride-rich lipoproteins and on the lipid profile in patients with acne. Arch Dermatol Res. 2006;297:403–408.
    1. Wiegand UW, Chou RC. Pharmacokinetics of oral isotretinoin. J Am Acad Dermatol. 1998;39:S8–12.
    1. Nau H. Teratogenicity of isotretinoin revisited: species variation and the role of alltrans-retinoic acid. J Am Acad Dermatol. 2001;45:S183–S187.
    1. Waraich P, Goldner EM, Somers JM, Hsu L. Prevalence and incidence studies of mood disorders: a systematic review of the literature. Can J Psychiatry. 2004;49:124–138.
    1. Marqueling AL, Zane LT. Depression and suicidal behavior in acne patients treated with isotretinoin: a systematic review. Semin Cutan Med Surg. 2005;24:92–102.
    1. Jick SS, Kremers HM, Vasilakis-Scaramozza C. Isotretinoin use and risk of depression, psychotic symptoms, suicide, and attempted suicide. Arch Dermatol. 2000;136:1231–1236.
    1. Hersom K, Neary MP, Levaux HP, Strauss JS. Isotretinoin and anti-depressant pharmacotherapy: a prescription sequence symmetry analysis. J Am Acad Dermatol. 2003;49:424–432.
    1. Bigby M. Does isotretinoin increase the risk of depression? Arch Dermatol. 2008;144:1197–1199.
    1. Bernstein CN, Nugent Z, Longobard T, Blanchard JF. Isotretinoin is not associated with inflammatory bowel disease: a population-based case-control study. Am J Gastroenterol. 2009;104:2774–2778.
    1. Crockett SD, Porter CQ, Martin CF, Sandler RS, Kappelman MD. Isotretinoin use and the risk of inflammatory bowel disease: a case-control study. Am J Gastroenterol. 2010;105:1986–1993.
    1. Phillips TJ. An update on the safety and efficacy of topical retinoids. Cutis. 2005;75:S14–S24.
    1. Kockaert M, Neumann M. Systemic and topical drugs for aging skin. J Drugs Dermatol. 2003;2:435–441.
    1. Samuel M, Brooke RC, Hollis S, Griffiths CE. Interventions for photodamaged skin. Cochrane Database Syst Rev. 2005;25:CD001782.
    1. Zeichner JA, Stern DW, Uliasz A, Itenberg S, Lebwohl M. Placebo-controlled, double-blind, randomized pilot study of imiquimod 5% cream applied once per week for 6 months for the treatment of actinic keratosis. J Am Acad Dermatol. 2009;60:59–62.
    1. Tangrea JA, Edwards BK, Taylor PR, Hartman AM, Peck GL, Salasche SJ, et al. Long-term therapy with low-dose isotretinoin for prevention of basal cell carcinoma: a multicenter clinical trial. Isotretinoin-Basal Cell Carcinoma Study Group. J Natl Cancer Inst. 1992;84:328–332.
    1. Levine N, Moon TE, Cartmel B, Bangert JL, Rodney S, Dong Q, et al. Trial of retinol and isotretinoin in skin cancer prevention: a randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group. Cancer Epidemiol Biomarkers Prev. 1997;6:957–961.
    1. Otley CC, Stasko T, Tope WD, Lebwohl M. Chemoprevention of nonmelanoma skin cancer with systemic retinoids: practical dosing and management of adverse effects. Dermatol Surg. 2006;32:562–568.
    1. Epstein E. Quantifying actinic keratosis. Am J Clin Dermatol. 2004;5:141–144.
    1. Atkins D, Bang RH, Sternberg MR, Chen SC. Reliable methods to evaluate the burden of actinic keratosis. J Invest Dermatol. 2006;126:591–594.
    1. Weinstock MA, Bingham SF, Cole GW, Eilers D, Naylor MF, Kalivas J, et al. Reliability of counting actinic keratosis before and after brief consensus discussion. Arch Dermatol. 2001;137:1055–1058.
    1. Cockerell CJ, Wharton JR. New histopathological classification of actinic keratosis (incipient intraepidermal squamous cell carcinoma) Drugs Dermatol. 2005;4:462–467.
    1. Röwert-Huber J, Patel MJ, Forschner T, Ulrich C, Eberle J, Kerl H, et al. Actinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification. Br J Dermatol. 2007;156:S8–12.
    1. Schmitt JV, Miot HA. Actinic keratosis: a clinical and epidemiological revision. An Bras Dermatol. 2012;87:425–434.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel